A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
Recruiting · NCT07601074 · Registry updated 2026-08-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV) | High-risk Human Papillomavirus Infection; Human Papilloma Virus (HPV) | Recruiting | Phase 2 | 2026-08-25 | NCT07601074 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Advanced Research Projects Agency for Health (ARPA-H) | 9 |
| Daré Bioscience, Inc. | 3 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Alpine Research Organization, Inc. | Layton | United States | 2 |
| Applied Research Center of Arkansas/Cornerstone Clinic for Women | Little Rock | United States | 1 |
| Precision Clinical Trials-Arizona | Phoenix | United States | 1 |
| Seattle Clinical Research Center | Seattle | United States | 8 |